News

In the study, published in Nature Biotechnology, researchers used their new system to correct disease-causing mutations in the eyes of two mouse models of genetic blindness, partially restoring their vision.

Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

The study showed that a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye.

The company has divested its Coherus Ophthalmology subsidiary to Sandoz, Inc. for upfront all-cash consideration of $170 million.

Investigators believe that AMD and cancer may have similar risk factors in common.

ChatGPT-4 (OpenAI) had an overall “fair” performance when answering multiple-choice ophthalmic questions unrelated to multifocal imaging.

Early detection of the disease is key to optimal patient outcomes

Day 2 program of the 2024 COPHy conference.

The approval marks the first new steroid on the ophthalmic market in more than 15 years.

The 2024 15th annual Controversies in Ophthalmology Congress will convene March 15 and 16 in Athens, Greece.

The supplement is specifically crafted to promote healthy intraocular pressure (IOP), nurturing the well-being of retinal ganglion cells, and sustain the health of the retinal nerve fiber layer while boosting memory and concentration.

Mobile cameras allow University of Colorado ophthalmology residents working in hospital settings to conduct more comprehensive and efficient patient evaluations.

According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.

Lowe syndrome, a genetic disease, affects about 1 in 500,000 people in the general population.

According to the company, Stargardt disease is an orphan blindness disease that affects approximately 35,000 people in the United States.

RVO can significantly reduce vision-related quality of life, particularly in more severe cases.

The authors suggested genetic mutation may relax the body’s defences and allow harmful bacteria to reach the eye.

According to the company, 2,500 clinical and peer-reviewed studies that span 235 disease states have demonstrated the clinical utility of Optos technology.

The company will add Pravin U. Dugel, MD, as executive director, and add Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, PhD, MBBS, to its management team.

The treatment is a minimally invasive intravitreal injection that can be performed with a topical anesthetic.

A new initiative from Prevent Blindness will kick off to provide free educational resources on retinopathy of prematurity.

AI matched and outshone human specialists.

Researchers have found that the interactive release of anti-inflammatory drugs depend on the level of retinal degeneration. A customized treatment approach is expected to be developed to reduce patients’ inconvenience of having multiple shots.

A new study shows that much of an older person with visual impairment's physical activity is achieved at home. Improved home lighting can help increase those at-home activity rates.

The platform to streamline clinical decision workflows, management of teleophthalmology, referral decisions and patient management while improving clinic efficiencies.